Will mRNA vaccines one day protect against HIV? Three investigational mRNA vaccines, all designed to combat HIV, have entered Phase I testing.
List view / Grid view
The Scripps Research Institute
Moderna and IAVI take steps towards HIV vaccination, with initiation of a trial dosing patients with HIV immunogens delivered by mRNA.
Scientists call for investment into novel, potentially pan-virus vaccines to prevent the next pandemic
Investment into vaccines based on broadly neutralising antibodies could allow pan-virus vaccines to be developed and stockpiled before the next pandemic, say researchers.
A new study suggests breast cancer patients taking palbociclib/letrozole combination therapy should avoid foods rich in xenoestrogens...
The findings from the two pivotal phase 3 trials pave the way for ozanimod to enter the New Drug Approval process with the FDA...
20 March 2009 | By
For years biologists have worked to develop alternatives to traditional therapeutics. These efforts, in areas such as stem cell based and gene therapies, have received much fanfare in popular media outlets, raising expectations among the general public. This excitement may have contributed to the hasty progression of early gene therapy…
28 November 2006 | By John R. Yates, III, Department of Cell Biology, The Scripps Research Institute, Thierry Rabilloud, DBMS/BMCC, Alexander W. Bell, Montreal Proteomics Centre, McGill University and John J. M. Bergeron, Department of Anatomy and Cell Biology, McGill University, Quebec
Over the last ten years the Proteomics field has been a technologically dynamic area. New methods and techniques help drive the field to achieve more sophisticated measurements that yield increasingly larger volumes of data and information. This creates several problems.